OBJ Limited Competitors

Each year, millions of people hear the words no one wants to hear: "You have cancer." And behind each diagnosis lies a unique story, a family that deserves hope, a future that's worth fighting for. We know that no two treatment journeys are the same and delivering care is far from simple. It's complex, urgent, and deeply human. That’s why we don’t back down from challenges—we rise to them. From the smallest tumor change to the toughest clinical decisions, we see every obstacle as an opportunity to progress. That is what drives us. The people undergoing treatment. The clinicians providing the care. We are united in purpose. Together, we can create a world where every patient has access to the highest standard of care. This is our commitment because for everyone, it's personal. We are leading the innovation in personalized radiation therapy solutions. We are Elekta. Elekta reserves the right to remove any comment and to restrict access to its page at its sole discretion, without prior notice. The presence of user comments does not imply endorsement by Elekta, and Elekta makes no representations regarding the accuracy of such comments. User-generated content does not necessarily reflect the views, values, or positions of Elekta.

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 825* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,400 employees worldwide. *As of March 2026 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at PV@hikma.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.